Every year, 6300 women and 50 men receive a terrible diagnosis: breast cancer! After the age of 50, the risk of developing breast cancer increases significantly. According to the Cancer League, a quarter of those affected are under 50 at the time of diagnosis.
Pharmaceutical companies have been searching for solutions to the disease for decades and have had some success. Today, 87 percent of people are still alive five years after being diagnosed with breast cancer. Now Novartis has achieved another academic success. As the drug company explains, results from a phase II study show that breast cancer patients treated with the drug Kisqali live longer.
He lived for a year – the disease did not return
Specifically, the patients in the “Right Choice” study were treated with Kisqali and endocrine, that is, anti-hormonal therapy, as Novartis explains. This combination has been compared with combination chemotherapy. The focus was on first-line treatment of premenopausal and perimenopausal patients with aggressive forms of HR+/HER2- metastatic breast cancer.
Patients treated with Kisqali therapy lived almost a year without disease recurrence. In the statement, it was stated that this situation underlines the superiority of the treatment for this patient group, which is difficult to treat. Novartis presents this data at the 2022 San Antonio Breast Cancer Symposium in the United States. (nim/SDA)